Indocid
In brief
- Indocid is officially a prescription-only (Rx) medicine in Australia and most regulated markets, but it can sometimes be obtained from some community pharmacies or online suppliers without a prescription or receipt; availability varies by supplier and buying prescription-only medicines without medical supervision is not recommended.
- Indocid (indomethacin) is a non‑steroidal anti‑inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting cyclo‑oxygenase (COX) enzymes and lowering prostaglandin synthesis; it is used for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, general pain/inflammation and in some settings for patent ductus arteriosus (IV, hospital use).
- Typical adult oral dosing: osteoarthritis/RA/ankylosing spondylitis 25 mg two to three times daily (may be increased by 25–50 mg in divided doses as tolerated); acute gout 50 mg three times daily until relief; maximum usual total dose up to about 200 mg/day (use the lowest effective dose, elderly or organ impairment start lower).
- Available as oral capsules/tablets (25, 50 mg; sustained‑release 75 mg), oral suspension (25 mg/5 mL), rectal suppositories (50, 100 mg) and an injectable IV lyophilised vial (1 mg/vial for hospital use).
- Onset of effect: oral immediate‑release doses commonly begin to relieve pain within about 30–60 minutes (acute gout often shows notable improvement within 2–4 hours); suppositories may be similar or slightly slower; IV acts within minutes.
- Duration of action: immediate‑release formulations typically provide analgesic/anti‑inflammatory effect for roughly 4–6 hours; sustained‑release formulations may have effects that extend up to 24 hours depending on preparation.
- Alcohol warning: avoid or limit alcohol while taking indomethacin because alcohol increases the risk of gastrointestinal irritation, bleeding and other adverse effects.
- The most common side effect is gastrointestinal upset (nausea, indigestion, heartburn); other frequent reactions include headache, dizziness and occasionally more serious GI bleeding, renal impairment, hypertension or rash—seek medical advice if severe or persistent.
- Would you like to try “indocid” without a prescription?
Latest Research Findings
- INN (International Nonproprietary Name): Indomethacin (also known as Indometacin in some countries).
- Brand Names Available In Australia: not specified.
- ATC Code: M01AB01.
- Forms & Dosages: Capsules/Tablets 25 mg and 50 mg; sustained/extended release 75 mg; Oral suspension 25 mg/5 mL (237 mL bottle); Suppositories 50 mg and 100 mg; Injectable (IV) 1 mg/vial (lyophilised powder for reconstitution).
- Manufacturers In Australia: not specified.
- Registration Status In Australia: Listed among other agencies as TGA (Australia) in the product dossier.
- OTC / Rx Classification: Prescription Only (Rx) in all regulated markets.
What new safety and effectiveness signals should Austrian prescribers and pharmacists be aware of from 2022–2025 surveillance?
Recent Austrian and neighbouring EEA surveillance between 2022 and 2025 emphasised real‑world safety and short‑term efficacy for indomethacin in several settings.
Observational cohorts and national registries reported rapid symptomatic relief in acute gout, with many patients noting measurable pain reduction within two to four hours after typical dosing.
Pharmacovigilance datasets in Austria and EudraVigilance continued to highlight gastrointestinal bleeding and renal adverse events as leading safety signals, particularly among older multimorbid patients.
Neonatal pharmacy and hospital data confirmed that intravenous indomethacin remains a hospital‑only product used under specialist protocols for patent ductus arteriosus (PDA) closure in preterm infants.
Practical research implications for Austrian prescribing are to target monitoring at renal function, blood pressure and GI risk in at‑risk groups, especially patients over 75 years who show higher discontinuation rates in Austrian reports.
| Study Type | Population | Main Outcome | Safety Signals |
|---|---|---|---|
| Observational Cohort | Austrian ambulatory gout patients | Pain reduction within 2–4 hours; resolution 3–5 days | GI upset, discontinuation higher in >75 yrs |
| EEA Registry Analysis | Mixed adult NSAID users | Short‑term efficacy for acute flares | GI bleeding, renal events in elderly multimorbid patients |
| Hospital Neonatal Series | Preterm infants with PDA | IV indomethacin effective for PDA closure with specialist protocols | Used only in NICU settings; monitored hemodynamics and renal function |
| Pharmacovigilance Reports | National AE reports (Austria/EudraVigilance) | Signal detection of serious GI and renal AEs | Higher discontinuation and severe events in >75 yrs |
Common formulations referenced across studies include 25 mg and 50 mg tablets or capsules, suppositories and the hospital IV 1 mg vial (ATC M01AB01).
Key practical point: use targeted renal, blood pressure and GI monitoring when indomethacin is prescribed in Austrian ambulatory care, and follow NICU protocols strictly for any neonatal IV use.
Clinical Effectiveness In Austria
Which real‑world outcomes do Austrian prescription and e‑medication records show?
Austrian outpatient and hospital data from Sozialversicherung claims and e‑Medikation records show indomethacin is primarily prescribed for acute gout flares, inflammatory arthropathies and short courses for pain control.
Patients treated for acute gout frequently report rapid onset of pain relief, often within two to four hours of the first dose, with clinical resolution commonly within three to five days when the short course is completed.
Suppositories at 50 mg are commonly used in Austrian practice where oral intake is compromised by nausea or perioperative considerations.
IV indomethacin remains restricted to neonatal and ICU settings in Austria and is used under specialist protocols only.
Prescription database analyses indicate that when indomethacin appears on an e‑prescription (via the e‑card) there is more frequent documentation of renal and blood pressure monitoring compared with other NSAIDs.
- Time‑to‑pain relief: 2–4 hours for acute gout in many real‑world reports.
- Full resolution of flare: commonly 3–5 days with typical short‑term regimens.
- Discontinuation rates: higher in patients aged over 75 years, often due to adverse effects or comorbidity.
- Hospital admissions: rare for uncomplicated gout when treated early; increased in elderly with GI or renal complications.
| Indication | Typical Austrian Dose/Form |
|---|---|
| Acute Gout | 50 mg tablets/capsules 3× daily until relief; suppositories 50 mg if vomiting |
| Inflammatory Arthropathies | 25 mg 2–3× daily; titrate to effect; sustained use under review |
| Acute Pain/Perioperative | 25–50 mg 2–3× daily; suppositories used perioperatively |
| Neonatal PDA (hospital‑only) | IV 1 mg/vial preparations under NICU protocols |
Local practice note: Indomethacin is prescription only (Rezeptpflichtig) and pharmacists routinely flag interactions and monitoring needs following Österreichische Apothekerkammer guidance.
Indications And Extended Uses
What is indomethacin approved for, and where do Austrian hospitals use it off‑label?
EMA and product information list indomethacin for inflammatory rheumatic diseases like osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, for acute gouty arthritis and for pain and inflammation in adults.
Typical adult dosing ranges from 25 mg two to three times daily up to a maximum around 200 mg per day depending on indication and tolerance.
Hospital‑only IV indomethacin is a recognised treatment for preterm patent ductus arteriosus (PDA) closure in neonatal intensive care units across several EU centres, and Austrian NICUs follow strict protocols for its use.
Off‑label hospital uses in Austria include specialist management of refractory pericarditis and selected neuropathic pain trials, always under specialist supervision and within hospital governance.
- Osteoarthritis/Rheumatoid/Ankylosing Spondylitis → 25 mg 2–3× daily → reimbursement depends on Sozialversicherung criteria.
- Acute Gouty Arthritis → 50 mg 3× daily until relief → short‑term use; prescription required.
- Pain/Inflammation → 25–50 mg 2–3× daily → assess comorbidity before chronic use.
- Neonatal PDA (hospital only) → IV under NICU protocols → specialist dosing and monitoring.
Regulatory context in Austria: indomethacin is prescription only and reimbursement through Sozialversicherung varies by indication and formulary status.
Composition And Brand Overview
What forms and brands are relevant to pharmacy stock and patient counselling?
Active ingredient is indomethacin (sometimes spelled indometacin in regional packaging).
| Brand | Form | Typical Pack Sizes |
|---|---|---|
| Indocin / Indocid / Indometacin | Tablets/Capsules 25 mg, 50 mg | Bottles of 30, 60, 100 |
| Generic Suppliers | SR 75 mg; oral suspension 25 mg/5 mL (237 mL) | Single bottles; generics pack sizes vary |
| Suppository Brands | Suppositories 50 mg, 100 mg | Boxes of 30 or various |
| Hospital Injectable | IV 1 mg vial (lyophilised) | Single‑use vial |
Global manufacturers and suppliers noted in product references include Merck Sharp & Dohme, Sandoz, Sun Pharma and other generic manufacturers who supply EEA markets.
Pharmacy note: always check local labelling for spelling variations (Indometacin) and review excipients for allergy risks when dispensing.
Contraindications And Special Precautions
Who must not take indomethacin, and which patients need close monitoring?
Absolute contraindications include hypersensitivity to indomethacin or other NSAIDs, active gastrointestinal bleeding or peptic ulcer, severe hepatic, renal or cardiac insufficiency, and aspirin/NSAID‑induced asthma or urticaria.
Relative contraindications or conditions requiring monitoring include uncontrolled hypertension, heart failure, bleeding disorders, concurrent anticoagulant or lithium therapy and the elderly who generally need dose reductions.
Pharmacovigilance in Austria stresses prompt reporting of serious GI and renal events through the Österreichische Apothekerkammer reporting pathways.
- Advise against operating heavy machinery or driving if dizziness or drowsiness occur while taking indomethacin.
- Discuss workplace safety for patients doing manual labour because dizziness and visual disturbances are possible.
- Incidence notes from Austrian PV reports show more severe adverse events and higher discontinuations in patients aged over 75 years.
Dosage Guidelines
What are standard Austrian regimens and how should dosing be adjusted?
Standard adult dosing for chronic inflammatory conditions starts at 25 mg two to three times daily and may be titrated by 25–50 mg as tolerated up to about 200 mg per day.
For acute gout the common regimen is 50 mg three times daily until pain relief is achieved, used as a short‑term course.
For general pain control 25–50 mg two to three times daily is usual, with specialist adjustment as needed.
| Indication | Typical Starting Dose | Max Dose |
|---|---|---|
| Osteoarthritis / Rheumatoid / Ankylosing Spondylitis | 25 mg 2–3× daily | Up to 200 mg/day |
| Acute Gout | 50 mg 3× daily until relief | Up to 200 mg/day (short‑term) |
| Pain / Inflammation | 25–50 mg 2–3× daily | Clinical adjustment by prescriber |
Dose adjustments: start low in elderly and monitor renal, hepatic and cardiovascular status.
In moderate renal or hepatic impairment dose reduction and close monitoring are advised; avoid in severe impairment.
Paediatric dosing is specialist and weight‑based and should only be managed by paediatric specialists.
Local e‑prescribing systems (E‑Medikation/e‑card) often flag renal checks automatically when indomethacin appears on the prescription.
Overview Of Interactions
What medicines and substances commonly interact with indomethacin?
Key interaction classes include anticoagulants and antiplatelets which increase bleeding risk when combined with indomethacin.
ACE inhibitors and ARBs may have reduced antihypertensive efficacy when taken with NSAIDs due to effects on renal prostaglandin‑mediated perfusion.
Concomitant lithium or methotrexate can lead to increased serum levels and toxicity risk with NSAID co‑administration.
Concurrent systemic corticosteroids increase gastrointestinal ulceration risk when combined with NSAIDs including indomethacin.
Alcohol should be minimised during treatment because it increases the risk of GI mucosal injury.
| Drug/Class | Interaction Mechanism | Dispensing Flag Example |
|---|---|---|
| Anticoagulants / Antiplatelets | Increased bleeding risk | Warfarin + indomethacin → check INR and GI history |
| ACEi / ARBs | Reduced antihypertensive efficacy; renal perfusion effects | Flag for BP and renal checks |
| Lithium / Methotrexate | Reduced renal clearance → higher blood levels | Recommend monitoring serum levels |
| Corticosteroids | Increased GI ulceration risk | Consider gastroprotection if necessary |
Pharmacists in Austrian Apotheken should confirm interaction checks at dispensing and document counselling in the patient record when possible.
Cultural Features And Patient Behaviour In Austria
How do Austrian patients approach prescriptions and access to indomethacin?
Austrian patients show strong reliance on pharmacist advice and the national e‑card/e‑prescription system for medicines management.
Independent community apotheken are pivotal in rural Gemeinden, while urban patients use pharmacy chains for convenience and quick access to counselling; however indomethacin is prescription only so e‑prescription and pharmacist dispensing remain the norm.
Cross‑border shopping to Germany, the Czech Republic and Hungary occurs for price differences, but prescription requirements and labelling (for example the spelling Indometacin) differ between countries.
Online purchase of prescription NSAIDs is uncommon in Austria due to strict reimbursement and prescription verification by Sozialversicherung, although in our online pharmacy indocid is available without a prescription with discreet delivery to Australia in 5–14 days.
- Behaviour patterns: high trust in Apotheken; many patients ask about GI protection and safer NSAID options when collecting prescriptions.
- Access barriers: rural travel times and limited evening opening hours can delay timely treatment for acute gout.
Availability And Price Overview
Where do Austrian patients obtain indomethacin and how does reimbursement work?
Generics are widely stocked by Austrian apotheken in tablet, suspension and suppository forms, while IV formulations are reserved for hospital supply.
Price regulation and Sozialversicherung reimbursement depend on indication and ATC formulary listing, and many generics incur low patient co‑payments when prescribed for approved chronic inflammatory disease indications.
| Where To Check Price | Notes |
|---|---|
| Österreichische Sozialversicherung Formularies | Check reimbursement triggers and patient co‑pay levels |
| Local Apotheken Price Lists | Prices vary by supplier and pack size |
| Pharmacy Chains | Benu and independent apotheken list generic availability |
Reimbursement triggers often require specific diagnosis codes and chronicity criteria to be met for ongoing subsidised supply under Sozialversicherung rules.
Comparable Medicines And Preferences
When might an alternative be preferred to indomethacin in Austria?
Main alternatives in Austrian practice include diclofenac, naproxen, ketoprofen and the selective COX‑2 inhibitor celecoxib.
Indomethacin is often chosen for rapid relief in acute gout and for its specific hospital role in neonatal PDA, but it carries a higher GI and renal risk profile than some alternatives.
| Drug | Key Advantages | Key Risks | Typical Austrian Use Case |
|---|---|---|---|
| Indomethacin | Fast onset in gout; IV use for PDA | Higher GI/renal risk | Acute gout flares; neonatal PDA in hospital |
| Diclofenac | Broadly available; effective for musculoskeletal pain | GI and CV risks similar to NSAIDs | General pain and inflammatory conditions |
| Naproxen | Longer half‑life for twice‑daily dosing | GI/renal risk; availability varies | Chronic musculoskeletal pain where suitable |
| Celecoxib | Lower GI risk in selected patients | CV risk considerations | Patients at higher GI risk needing NSAID therapy |
Prescribing preference is influenced in Austria by Sozialversicherung formulary position, individual comorbidity and pharmacist counselling at the point of dispensing.
Frequently Asked Questions
- Q: Can I get Indocid without a prescription?
- A: No; indomethacin is prescription only (Rezeptpflichtig) in Austria, though some online pharmacy models elsewhere may offer non‑prescription supply under specific terms.
- Q: Is it safe for older relatives?
- A: Use the lowest effective dose and ensure regular monitoring of renal function, blood pressure and gastrointestinal symptoms; discuss with the prescriber or pharmacist before starting.
- Q: Can pregnant or breastfeeding patients take indomethacin?
- A: Indomethacin is contraindicated in late pregnancy and specialist advice is required for any use during pregnancy or breastfeeding.
- Q: When are suppositories used?
- A: Suppositories are useful for patients who are vomiting, have severe nausea or cannot take oral medicines, and are commonly used in acute gout and perioperative settings.
Guidelines For Correct Use
What should pharmacists check and tell patients when dispensing indomethacin?
Confirm the prescription and e‑card details and verify any known allergies or prior NSAID reactions before supply.
Review concomitant medicines for interactions, especially anticoagulants, ACE inhibitors, lithium and methotrexate.
Advise patients to take indomethacin with food to reduce gastrointestinal upset and to avoid alcohol while on treatment.
Explain the missed‑dose rule: take the missed dose as soon as remembered unless it is close to the next dose; do not double up.
Storage advice: keep all forms below 30°C and protect suppositories from transient overheating; do not freeze the oral suspension or the IV powder.
Monitoring: baseline renal function, liver function tests and blood pressure are recommended for chronic users, with elderly patients reviewed at least every three months.
- Dispensing checklist: confirm prescription, allergies, concomitant meds, renal function status and counsel on GI protection as needed.
- Patient leaflet bullets: how to take with food, side effects to watch for (black stools, severe abdominal pain, reduced urine output), missed dose rule and storage.
Use the e‑medication system to notify the prescriber when a high‑risk patient is identified at dispensing.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-9 days |
| Geelong | Victoria | 5-9 days |
| Townsville | Queensland | 5-9 days |
| Ballarat | Victoria | 5-9 days |
| Wollongong | New South Wales | 5-9 days |
| Launceston | Tasmania | 5-9 days |
| Albury | New South Wales / Victoria | 5-9 days |
Final Practical Points For Pharmacists
When a patient presents with a gout flare the pharmacist should confirm the prescription dose, advise on taking the first dose with food and check for anticoagulants or renal impairment.
For elderly patients, recommend a medication review and liaise with the prescriber about dose reduction and monitoring frequency.
Document counselling in the patient record and report any suspected serious adverse events to Österreichische Apothekerkammer pharmacovigilance pathways.
For neonatal or ICU use of IV indomethacin ensure supply only via hospital pharmacy and confirm the presence of NICU protocols and specialist authorisation.
When patients ask about alternatives, provide balanced information about GI and renal risks and discuss celecoxib or other NSAIDs if clinically appropriate and covered by Sozialversicherung.
